88
Participants
Start Date
January 15, 2019
Primary Completion Date
February 28, 2021
Study Completion Date
February 28, 2021
Secukinumab 150 milligram [Cosentyx]
For intervention description: see arm/group description
RECRUITING
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Frederiksberg, Frederiksberg
RECRUITING
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Glostrup Municipality
RECRUITING
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Gentofte, Hellerup
NOT_YET_RECRUITING
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Nordsjællands Hospital Hillerød, Hillerød
NOT_YET_RECRUITING
Reumatologisk afdeling, Sjællands Universitetshospital, Køge, Køge
NOT_YET_RECRUITING
Reumatologisk Afdeling, Odense Universitetshospital, Odense
NOT_YET_RECRUITING
Kong Christian X´s Gigthospital, Gråsten
NOT_YET_RECRUITING
Reumatologisk Afdeling, Aarhus Universitetshospital, Aarhus
NOT_YET_RECRUITING
Reumatologisk Afdeling, Regionshospitalet Silkeborg, Silkeborg
NOT_YET_RECRUITING
Reumatologisk Afdeling, Regionshospitalet Nordjylland, Hjørring, Hjørring
Collaborators (1)
Novartis Healthcare A/S
INDUSTRY
Professor Mikkel Østergaard
OTHER